Evidence map›Paper›PMID 28536240›Full record

ArticleThe Journal of experimental medicine2017

Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes".

Carolin Daniel, Benno Weigmann, Harald von Boehmer

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Carolin DanielInstitute for Diabetes Research, Research Group Immune Tolerance in Type 1 Diabetes, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany carolin.daniel@helmholtz-muenchen.de.ORCID http://orcid.org/0000-0003-4698-7069
Benno WeigmannDepartment of Medicine 1, University of Erlangen-Nuremberg, Erlangen, Germany.ORCID http://orcid.org/0000-0002-2398-0844
Harald von BoehmerHarvard Medical School (em.), Boston, MA.ORCID http://orcid.org/0000-0002-9714-1613
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEHarvard University · USHelmholtz Zentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3

Indexed as

AnimalsDiabetes Mellitus, Type 1EpitopesEverolimusFemaleForkhead Transcription FactorsGastrointestinal MicrobiomeHumansImmune ToleranceImmunosuppressive AgentsInsulinMice, Inbred NODT-Lymphocytes, RegulatoryTOR Serine-Threonine KinasesVaccinationEpitopesEverolimusForkhead Transcription FactorsFoxp3 protein, mouseImmunosuppressive AgentsInsulinTOR Serine-Threonine Kinases

Identifiers

PMID28536240
PMCPMC5501570
OpenAlexW2619734090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.